Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMXO98C)

Drug Name
3-hydroxy-N,N,N-trimethylbenzenaminium iodide Drug Info
Synonyms
TMPH; 3-(Trimethylammonio)phenol iodide; m-(Dimethylamino)phenol methiodide; 3-Hydroxy-N,N,N-trimethylbenzenaminium iodide; 3-Oxyphenyl trimethylammonium iodide; (m-Hydroxyphenyl)trimethylammonium iodide; CHEMBL37773; AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, IODIDE; 2498-27-3; 3483-84-9 (Parent); 3-Hydroxyphenyltrimethylammonium Iodide; AC1L29MQ; Benzenaminium, 3-hydroxy-N,N,N-trimethyl-, iodide; KNPHMCQIKGHPRU-UHFFFAOYSA-N; m-hydroxyphenyltrimethylammonium iodide; LS-18453; (3-hydroxyphenyl)-trimethylazanium iodide
Cross-matching ID
PubChem CID
17250
CAS Number
CAS 2498-27-3
TTD Drug ID
D03PQH

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Base excision repair 1.97 9.75e-3 29/33 (87.88%) PARP2;PCNA;POLE2;...
IL-17 signaling pathway 1.88 3.41e-2 84/94 (89.36%) S100A8;S100A9;TRAF5;...
Hematopoietic cell lineage -1.69 3.38e-2 90/99 (90.91%) CD44;ITGA3;IL3RA;...
Fat digestion and absorption -1.72 2.72e-2 35/43 (81.4%) LIPF;AGPAT1;APOB;...
Linoleic acid metabolism -1.74 2.11e-2 21/29 (72.41%) PLA2G4C;PLA2G4A;CYP3A4;...
Thyroid cancer -1.79 1.33e-2 36/37 (97.3%) RXRA;BAK1;TFG;...
Pentose and glucuronate interconversions -1.85 5.94e-3 17/34 (50%) UGDH;AKR1B1;UGT2B4;...
Phenylalanine metabolism -1.85 6.48e-3 14/17 (82.35%) HPD;GOT1;AOC2;...
Complement and coagulation cascades -1.88 5.10e-3 76/85 (89.41%) SERPINA5;CFHR4;FGG;...
Metabolism of xenobiotics by cytochrome P450 -1.92 1.13e-3 49/77 (63.64%) CYP2B6;CYP2D6;GSTK1;...
Fatty acid degradation -1.93 1.27e-3 40/43 (93.02%) ACAT1;ECHS1;CPT2;...
beta-Alanine metabolism -1.94 0.00e+0 25/30 (83.33%) ACOX3;AOC2;DPYS;...
alpha-Linolenic acid metabolism -1.96 0.00e+0 17/25 (68%) FADS2;ACOX3;PLA2G4C;...
Retinol metabolism -1.98 0.00e+0 41/68 (60.29%) CYP1A2;AOX1;CYP26B1;...
Mineral absorption -2.00 0.00e+0 48/60 (80%) ATP2B4;HEPH;FTH1;...
Fatty acid elongation -2.14 0.00e+0 19/27 (70.37%) MECR;ELOVL6;TECR;...
Biosynthesis of unsaturated fatty acids -2.20 0.00e+0 21/27 (77.78%) ELOVL6;FADS2;TECR;...
PPAR signaling pathway -2.23 0.00e+0 66/74 (89.19%) HMGCS2;FADS2;ILK;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H